Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Baxter
Express Scripts
McKesson
Mallinckrodt

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

XGEVA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Tradename: XGEVA
Patents:88
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for XGEVA
Mechanism of ActionRANK Ligand Blocking Activity

Company Disclosures: US Patents for XGEVA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial Immunex Corporation (Seattle, WA) 2016-12-23 RX Orphan company
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial Amgen Inc. (Thousand Oaks, CA) 2017-04-16 RX Orphan company
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA) 2021-06-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for XGEVA

These patents were identified by searching patent claims

Supplementary Protection Certificates for XGEVA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 45/2010 Austria   Start Trial PRODUCT NAME: DENOSUMAB
2019C/008 Belgium   Start Trial PRODUCT NAME: APREMILAST,OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116
2010/035 Ireland   Start Trial PRODUCT NAME: DENOSUMAB (PROLIA ); NAT REGISTRATION NO/DATE: EU/1/10/618/001 20100526; FIRST REGISTRATION NO/DATE: EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 26/05/2010 IRELAND EU/1/10/618/001 26/05/2010 IRELAND EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 20100526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.